BioSpace News Archive

Ankyra Therapeutics today announced that is has entered into a strategic collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson*.

Stoke Therapeutics, Inc. today announced that management will present at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 4:20 p.m. ET.

Centogene N.V. announced that it has received a notification from the Nasdaq Stock Market LLC Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450.

The Collaborative Trajectory Analysis Project (cTAP), a global coalition in rare disease, has announced evidence to support patient-centric alternatives to the conventional use of genetically matched placebo controls in clinical trials for RNA-editing therapies in Duchenne Muscular Dystrophy (DMD).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

BioConsortia, Inc., a recognized leader in the field of gene-editing to unleash the power of microbes for crop protection, nitrogen-fixation and yield improvement, announced today that Dr. Damian Curtis, BioConsortia’s Director of Synthetic Biology and Genomics, will present “Unleashing the Power of Microbes to Meet the World’s Food Needs” at the 5th Annual CRISPR AgBio Congress.

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on February 8, 2023.

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Gopi Shankar, PhD, MBA, FAAPS, to the newly created position of Chief Development Officer (CDO).

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 1:00 p.m. ET.

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced the closing of its previously announced registered direct offering.